FLOXIN

Compare FLOXIN  to:
Compare
Compare

Generic Name for FLOXIN

Ofloxacin 200mg, 300mg, 400mg; tabs.

Legal Classification:

Rx

Pharmacological Class for FLOXIN

Quinolone.

Manufacturer of FLOXIN

Ortho-McNeil Pharmaceuticals, Inc.

Indications for FLOXIN

Susceptible infections including acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, acute pelvic inflammatory disease (PID), acute, uncomplicated cervical and urethral gonorrhea, urethritis, cervicitis, uncomplicated cystitis, uncomplicated skin and skin structure, complicated UTIs, prostatitis.

Adult dose for FLOXIN

≥18yrs: Take with full glass water. Bronchitis, pneumonia, uncomplicated skin and skin structure: 400mg every 12 hours for 10 days. Urethritis, cervicitis: 300mg every 12 hours for 7 days. Gonorrhea: 400mg once as a single dose. PID: 400mg every 12 hours for 10–14 days. Uncomplicated cystitis due to E. coli or K. pneumoniae: 200mg every 12 hrs for 3 days. Other uncomplicated cystitis: 200mg every 12 hrs for 7 days. Complicated UTIs: 200mg every 12 hrs for 10 days. Prostatitis due to E. coli: 300mg every 12 hours for 6 weeks. Severe hepatic impairment: max 400mg/day. Renal impairment: CrCl 20–50mL/min: give normal dose (loading dose) and increase dosing interval to 24 hours. CrCl <20mL/min: give normal dose once (loading dose) then ½ normal dose and increase dosing interval to 24 hours.

Children's dosing for FLOXIN

<18yrs: not recommended.

Warnings/Precautions for FLOXIN

Increased risk of tendinitis or tendon rupture esp. in patients >60yrs, or those with kidney, heart, or lung transplants. CNS disorders (e.g., cerebral arteriosclerosis, epilepsy) that increase seizure risk. Discontinue if CNS effects, photosensitization, allergic reactions, peripheral neuropathy, or tendon pain, inflammation or rupture occurs. History of QT prolongation or proarrhythmic conditions (eg, hypokalemia, bradycardia, recent MI). May mask symptoms of syphilis; test for syphilis before treating gonorrhea then follow-up after 3 months. Maintain adequate hydration. Avoid excessive sun or UV light. Monitor blood, renal, and hepatic function in prolonged use. Renal or severe hepatic impairment. Pregnancy (Cat.C), nursing mothers: not recommended.

Interactions for FLOXIN

Avoid drugs that prolong QTc interval (eg, Class IA or Class III antiarrhythmics, erythromycin, antipsychotics, tricyclics). Separate dosing of magnesium- or aluminum containing antacids and didanosine, sucralafate, iron, zinc, other metal cations (separate dosing by 2hrs). Increased risk of seizures with NSAIDs. May potentiate cyclosporine, theophylline, warfarin; monitor. May potentiate insulin, oral hypoglycemics (discontinue ofloxacin if hypoglycemia occurs). Increased risk of tendinitis and tendon rupture with corticosteroids. Monitor drugs metabolized by CYP450.

Adverse Reactions for FLOXIN

GI upset, dizziness, rash, pruritus, dysgeusia; CNS stimulation (eg, convulsions, nervousness, anxiety), hypersensitivity reactions, phototoxicity, tendinitis/rupture; rarely: peripheral neuropathy.

How is FLOXIN supplied?

Tabs 200mg, 300mg—50
Tabs 400mg—100

Related Disease:

Bronchitis, chronic
Infections, bacterial~systemic antiinfectives
Pneumonia

Related Resources

Phase 1 and 2 studies of solithromycin for the treatment of community-acquired bacterial pneumonia (CABP)

September 08, 2010

Cempra Pharmaceuticals announced that it is enrolling patients in a Phase 2 study of orally dosed solithromycin for the treatment of community-acquired bacterial pneumonia (CABP), as well as the initiation of a Phase 1 study of intravenous (IV) solithromycin.

Tygacil labeling updated to include increased mortality risk

September 01, 2010

The FDA is reminding healthcare professionals that intravenous Tygacil (tigecycline, from Pfizer) can increase mortality risk in the treatment of serious bacterial infections.

Phase 3 study of torezolid for acute bacterial skin and skin structure infections

August 30, 2010

Trius Therapeutics announced the initiation of its Phase 3 study of oral torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

FDA warns of eosinophilic pneumonia risk with Cubicin

July 29, 2010

The FDA has notified healthcare professionals and patients about the potential for developing eosinophilic pneumonia while receiving the antibiotic Cubicin (daptomycin, from Cubist).

FDA warns of counterfeit Tamiflu product

June 18, 2010

The FDA has warned consumers about a potentially harmful product represented as "Generic Tamiflu" sold over the Internet.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions